摘要
目前偏头痛的急性期治疗包括非特异性止痛和曲坦类药物治疗。这些药物的局限性包括:在许多患者中缺乏疗效、不良反应多、曲坦类药物在心血管疾病患者中的禁忌证等,这些都表明对偏头痛新疗法的需求尚未得到满足。对5-羟色胺(5-HT)药理学的研究促进了曲坦类药物(5-HT1B/1D受体激动剂)的发展,其中一些是在5-HT_(1F)受体上起作用。对降钙素基因相关肽(CGRP)作用的探索引起了CGRP受体拮抗剂的发展。本文就近几年针对CGRP和5-HT_(1F)受体的偏头痛急性治疗的主要进展综述如下。
Present,the acute treatment of migraine includes non-specific pain relief and triptan drugs.The limitations of these drugs include:lack of efficacy in many patients,many side effects,contraindications of triptan drugs in patients with cardiovascular disease,and so on,which indicate that the demand for new treatments for migraine has not been met.The pharmacological study of 5-hydroxytryptamine(5-HT)has promoted the development of triptan drugs(5-HT1B/1D receptor agonists),some of which act on 5-HT_(1F)receptors.The exploration of the role of calcitonin gene-related peptide(CGRP)has led to the development of CGRP receptor antagonists.This article reviews the main progress in the acute treatment of migraine with CGRP and 5-HT_(1F)receptors in recent years.
作者
陈娅茹
宰风雷
CHEN Ya-ru;ZAI Feng-lei(Changzhi Medical College,Changzhi Shanxi,046000,China;Heping Hospital Affi liated to Changzhi Medical College,Changzhi Shanxi,046000,China)
出处
《中华养生保健》
2022年第21期64-68,共5页
CHINESE HEALTH CARE
基金
山西省长治市长治医学院附属和平医院青年启动基金项目针刺“蝶腭穴”治疗丛集性头痛的临床应用研究(编号:HPYJ201919)。
